6. Parkinson disease
2,123 clinical trials,   2,046 drugs   (DrugBank: 324 drugs),   183 drug target genes,   198 drug target pathways

Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-003962-41-GB
(EUCTR)
23/03/202006/02/2020Trial of Ondansetron as a Parkinson's HAllucinations Treatment: TOP HATTrial of Ondansetron as a Parkinson’s HAllucinations Treatment - TOP HAT Adults aged over 18 years with Parkinson's disease and visual hallucinations
MedDRA version: 21.1;Level: LLT;Classification code 10047570;Term: Visual hallucinations;System Organ Class: 100000004873;Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
Trade Name: Ondansetron 8 mg film-coated tablets
Product Name: Ondansetron 8 mg film-coated tablets
INN or Proposed INN: Ondansetron hydrochloride dihydrate
University College LondonNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
216Phase 2United Kingdom